Theranos case highlights the challenges in venture capital

The collapse of Theranos and the subsequent travails of its founder, Elizabeth Holmes, may well have cooled somewhat the formerly white-hot search of venture capitalists for the next great high-tech unicorn.

After the verdict, Bijan Salehizadeh, holder of an MD from the Columbia University College of Physicians and Surgeons (1999), and an investor at Highland Capital Partners, reminisced for The New York Times about his reluctance to invest in Theranos in its early years, and how he came to question that judgment while listening to the venture capitalists hanging out at the Rosewood . . .

Continue Reading

Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Annual subscriptions get you the most bang for your buck, including access to Alternatives Watch Research articles and out Annual Investor Compendium.

Monthly subscriptions and discounted corporate plans for up to 100 members also available.

Christopher Faille

Christopher Faille has written on a variety of legal, regulatory, and financial issues for decades. He is the author of "The Decline and Fall of the Supreme Court" (1995), for example, and the coauthor, with David O'Connor, of "Basic Economic Principles" (2000). He was an early reporter with Lipper HedgeWorld and has contributed to Forbes and to the Hedge Fund Law Report.

Related Articles

Back to top button

Start Your Days in the Know


Get fresh alts intel in your inbox with our FREE newsletter!

You have Successfully Subscribed!